Brello Health Review: The Upfront Price Behind Its Monthly GLP-1 Offers

Brello Health’s advertised monthly prices are not the amounts a new customer should expect to pay at checkout. Its compounded semaglutide offer starts at $133 per month, but the documented three-month plan collects $399 initially. Compounded tirzepatide starts at $166 per month, with $499 collected for the three-month plan. Both renew every 11 weeks, rather than every three calendar months. That difference makes Brello a service to evaluate by payment date and upfront exposure—not just by the largest monthly number on a landing page.

This documentary review examines Brello’s prices, included services, pharmacy arrangements and refund boundaries using sources consulted October 19, 2026. The offering is concrete, but several documents pull in different directions: medication pages advertise a price lock while the homepage allows checkout-dependent pricing; refund terms contain exceptions absent from the general terms; and delivery policies disagree about packages marked delivered. None of those differences proves what will happen to a particular order. They do make a written, plan-specific explanation valuable before paying.

At a glance

Semaglutide payment: Compounded semaglutide starts at an advertised $133/month average; the three-month plan charges $399 initially and renews for $399 every 11 weeks.
Sources: [8]
Tirzepatide payment: Compounded tirzepatide starts at an advertised $166/month average, with a three-month minimum and $499 renewals every 11 weeks.
Sources: [5]
Longer prepaid option: The six-month tirzepatide plan charges $894 initially, advertises a $149/month average and renews for $894 every 22 weeks.
Sources: [4]
Payment precedes intake: Customers pay before completing the intake form. A clinician then determines whether the plan is appropriate; a prescription is not guaranteed.
Sources: [8] [2]
Refund timing matters: The detailed policy offers a full refund before review or after rejection without a prescription. After prescribing but before dispensing, a qualifying request within 24 hours carries a $50 deduction.
Sources: [3]

Read the checkout charge before the monthly average

Brello’s semaglutide page pairs its starting-at $133 monthly figure with a three-month minimum and a $399 charge today. The corresponding tirzepatide offer starts at $166 monthly and renews at $499 every 11 weeks. These are compounded medications, not identified FDA-approved branded products. The semaglutide plan lists syringes, needles and injection instructions, but the supplied documents do not clearly specify the full formulation, concentration, additives or anatomical administration route.

The six-month tirzepatide option collects $894 today and advertises an average of $149 per month. Its recurring charge is $894 every 22 weeks. No monthly installment alternative is documented for these offers. A lower displayed average therefore means accepting a larger initial payment, not necessarily a smaller bill when enrolling. Our guide to the first GLP-1 payment explains why those two figures need separate places in a household budget.

The semaglutide page also advertises “Save 33%” alongside a crossed-out $599 price and a $399 current price. That is Brello’s promotion, not an independently established comparison with other providers. More importantly, neither an 11-week nor a 22-week renewal is a calendar-quarter or half-year billing schedule. The table captures documented payment terms; it does not establish exact medication quantities, individualized prescriptions or the cancellation consequences of a plan’s stated minimum.

Documented prepaid offers and recurring charges
Plan	Initial charge and advertised average	Recurring charge
Compounded semaglutide, three-month plan	$399; starting at $133/month average	$399 every 11 weeks
Compounded tirzepatide, three-month plan	$499; starting at $166/month average	$499 every 11 weeks
Tirzepatide, six-month plan	$894; $149/month average	$894 every 22 weeks
Empowered+ semaglutide and NAD+, three-month plan	$598 upfront	$598 every 11 weeks
Empowered+ tirzepatide and NAD+, three-month plan	$698 upfront	$698 every 11 weeks

Sources: [8] [5] [4] [6]

Renewal promises need a plan-specific explanation

Brello’s medication pages advertise a price lock for new members: no extra fees, no increases when the dosage changes and no increases at renewal. That is a meaningful commercial promise. The homepage, however, says final pricing may vary by individual treatment plan and that the recurring rate is the applicable amount charged at checkout. Those statements may address different circumstances, but the supplied documents do not fully reconcile them. Save the offer and ask which wording governs your purchase.

The homepage says all plans require a three-month minimum, while a separate page offers the six-month plan. Both types use automatic renewal and “cancel anytime” language. The evidence does not supply the complete cancellation procedure or the advance notice needed to stop the next payment. Do not assume that canceling midway through a prepaid period returns unused money, or that the renewal falls on the same numbered day several months later.

For budgeting, obtain the next charge date, amount and cancellation method before enrollment. Ask whether canceling prevents only future charges and whether any minimum commitment remains relevant. These are narrower, more useful questions than asking simply whether the subscription is flexible. Our explanation of prepaid billing intervals provides a framework for comparing Brello’s week-based renewals with services that actually bill monthly.

Sources: [8] [5] [4] [2]

What the advertised bundle includes—and what remains outside it

Brello’s GLP-1 pages list medication if approved, shipping, discreet packaging and access to several nonmedication features. These include Brello Rise virtual fitness and nutrition classes, an app for tracking progress and connecting with the clinician, and a private Facebook community. The semaglutide page specifically includes syringes with needles and injection instructions. These documented inclusions make the offer more informative than a medication-only headline, although they do not establish the frequency or depth of clinical follow-up.

Brello also advertises access to both clinician and customer support throughout the process. The supplied evidence does not define guaranteed response times, scheduled review frequency or reevaluation requirements before renewal. Nor does it clearly settle laboratory costs, outside consultations, care for adverse effects, taxes or other expenses beyond the package. The “no extra fees” claim should therefore be clarified in relation to the services Brello controls, rather than treated as proof that every healthcare expense is covered.

The terms say the clinician does not participate in a payer network and neither the clinician nor Brello will submit reimbursement claims to commercial, federal or state payers for professional clinical services. That is not a complete statement of an individual insurance plan’s medication coverage, nor an exclusion establishing who may enroll. Before assuming reimbursement, distinguish the consultation from the prescription and ask your insurer directly. A useful comparison starts with what a program price includes, not its headline alone.

Sources: [8] [5] [10]

Paying starts the process, not a guaranteed prescription

Brello states that no intake form is required before payment. After checkout, customers complete the online form inside a telehealth account and should have government-issued identification ready. A healthcare professional then reviews the information to determine whether the plan is appropriate. The terms expressly allow clinicians to decline care or prescriptions for safety, potential misuse or other clinical or ethical reasons. The initial transaction therefore purchases entry into a review process, with medication conditional on approval.

The platform’s legal and clinical roles are separate. General terms identify Brello, LLC as the platform owner or controller and say Brello itself does not provide clinical advice. Virtual consultations come from clinicians using the website. The terms also say Brello does not confirm those clinicians’ credentials or licensing-board standing and assign that confirmation to the user. The supplied evidence does not identify individual treating clinicians, their clinical entity or their licenses; this review has not independently verified them.

Registration requires being at least 18 and located in the United States, but the terms restrict service to certain U.S. locations. The supplied availability material does not establish the exact states served. Clinical admission criteria, laboratory requirements and specific contraindication screening are also not fully documented. Separately, SMS terms name Brello, Inc., rather than Brello, LLC. That unexplained naming difference is another reason to request a clear identification of the billing business, treating practice and dispensing pharmacy.

Sources: [8] [2] [10] [7]

Refund eligibility narrows as an order progresses

The detailed refund policy provides the clearest staged explanation. Canceling before the health review qualifies for a full refund. A clinician’s determination that the customer is not an appropriate candidate also qualifies, provided no prescription has been issued. After prescribing but before dispensing, the policy allows a refund less a $50 professional service fee if the customer emails within 24 hours after Brello sends notice that review is complete and a prescription has been issued. The notification email’s timestamp controls.

That short window is not a general cooling-off period after delivery. Requests after it are ineligible under the stated provision, and medication becomes nonrefundable once dispensed. Meanwhile, the general terms label clinician and pharmacy fees nonrefundable without spelling out the detailed policy’s exceptions. The documents therefore deserve clarification together. Ask Brello to confirm the applicable refund stage in writing rather than assuming that a broad “cancel anytime” statement overrides dispensing or review-related limits.

Brello publishes info@brellohealth.com and 1-888-BRELLO-1 for cancellation and refund questions, although the specific post-prescription refund provision requires email. Its terms warn that email and text messages are not encrypted and advise against sending health or other sensitive information through them. A cancellation request can identify the administrative issue while asking for a secure route if clinical records are needed. Our guide to cancellation versus refunds explains why stopping renewal and recovering an earlier payment are separate outcomes.

Sources: [3] [10]

Pharmacy choice can change the payment arrangement

Brello’s terms identify AP Max, Inc., doing business as Southend Pharmacy, as the prescription-fulfillment provider. A tirzepatide page separately advertises shipment from a U.S.-based 503(a) pharmacy. Those are documented provider statements, not independent findings about licensing or compliance. Identifying a dispensing pharmacy also does not, by itself, establish which entity compounds a particular preparation. Request the pharmacy details and complete prescribed formulation rather than filling those gaps from the marketing description.

The terms allow customers to choose another pharmacy by notifying the clinician or emailing Brello. However, Brello does not guarantee that outside pharmacy’s services or pricing. The customer must pay that pharmacy directly and arrange pickup or other receipt; compounded prescriptions must transfer to another compounding pharmacy. Before using this route, ask how the prepaid package changes. The evidence does not establish that an outside prescription leaves the advertised all-in price intact or automatically generates a credit.

For approved orders in locations marked available without shipping delays, the FAQ says orders ship within three to five business days, with tracking emailed when available. That is dispatch, not arrival. The six-month page uses different wording: the first shipment arrives within three to five business days if approved, contains the first three months of treatment, and is followed by a second shipment sent approximately 11 weeks later. These are distinct promises, not one uniform delivery guarantee.

Sources: [10] [5] [6] [4]

Delivery disputes can create another upfront expense

The detailed refund policy asks customers to contact the dispensing pharmacy immediately about medication problems or possible dispensing errors, regardless of elapsed time. To be considered for replacement or refund under that policy, the issue must be reported within 48 hours of delivery. Incorrect addresses supplied by customers generally do not qualify for refund or reshipment, unless Brello’s system or processing caused the error. Confirming the checkout address is therefore a material financial safeguard.

For a package marked delivered but not received, the detailed policy treats carrier confirmation as presumptive rather than conclusive evidence. It requires an email within 48 hours, a signed nonreceipt statement, confirmation of the correct address and a police report where theft is suspected. A replacement may require another payment while the investigation proceeds. If nonreceipt is confirmed, Brello says it refunds that replacement payment within ten business days after the investigation ends—not that funds necessarily reach the bank within that period.

The FAQ is less accommodating: it considers fulfillment complete after carrier confirmation and says medications marked delivered cannot be reshipped. That conflict should be resolved before relying on replacement protection. Temperature handling is another documentation gap. FDA advises not using an injectable GLP-1 drug that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. Brello’s supplied materials do not specify the carrier, full temperature controls, storage conditions or supply expiration details.

Sources: [3] [6] [1]

Larger bundles and transfer protection need separate scrutiny

Brello’s optional combinations raise the amount at stake. Empowered+ advertises semaglutide with NAD+ for $598 initially and every 11 weeks, or tirzepatide with NAD+ for $698 on the same schedule. Thrive Forward lists semaglutide, sermorelin and NAD+ for $897 initially and every 11 weeks, with a displayed former price of $997. Its tirzepatide version lists $997 initially and every 11 weeks, against a former $1,099. Those prices document commercial bundles, not evidence of added clinical benefit.

Tirzepatide Transfer Protection says a customer may qualify for a first-order refund if the clinician does not continue treatment at or near the previous dose. Requirements include tirzepatide use within the preceding 30 days, proof of the existing prescription before review, a completed intake and clinician review, and no previous refund under the protection. This is conditional financial protection, not a promise that a clinician will preserve a particular prescription. The supplied evidence does not contain its complete terms.

Finally, price cannot resolve the regulatory distinction. FDA says compounded preparations are not approved and do not undergo its premarket safety, effectiveness and quality review. FDA recommends them when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence. Neither Brello’s bundle prices nor research on approved products demonstrates outcomes for its compounded preparations, and no provider-specific outcome evidence is supplied here.

Sources: [11] [9] [5] [2] [1]

Questions & answers

Can I pay Brello $133 each month for semaglutide?

The documented offer does not establish that option. The $133 figure is a starting monthly average for a prepaid three-month compounded semaglutide plan. The page charges $399 today and then $399 every 11 weeks until canceled. Confirm the actual checkout schedule rather than treating the average as an installment payment.

Sources: [8]

Does the six-month tirzepatide plan arrive all at once?

No. Brello documents two shipments. If approved, the first is described as arriving within three to five business days with the first three months of treatment; the second is sent approximately 11 weeks later. The plan charges $894 upfront and renews every 22 weeks. Exact medication quantities and expiration details are not established by that description.

Sources: [4]

What happens to my payment if the clinician rejects me?

The detailed policy promises a full refund if the clinician determines you are not an appropriate candidate and no prescription has been issued. It also offers a full refund for cancellation before review. These conditions differ from canceling after a prescription exists, when a short email deadline and $50 deduction can apply, and from cancellation after dispensing.

Sources: [3]

Will Brello bill my insurance for clinical services?

Its terms say the clinician does not participate in payer networks and neither the clinician nor Brello will submit reimbursement claims for professional clinical services. That statement does not settle your insurance plan’s drug benefits or promise reimbursement if you submit paperwork yourself. Ask separately about documentation and coverage rather than assuming the prepaid price is insurance-compatible.

Sources: [10]

Can I move a Brello prescription to my own pharmacy?

The terms permit another pharmacy after notifying the clinician or Brello. You then pay that pharmacy directly and arrange to obtain the medicine. Compounded prescriptions must transfer to another compounding pharmacy. Brello does not guarantee outside pricing or services, and the supplied evidence does not explain how choosing this option adjusts an already prepaid package.

Sources: [10]

Who should I contact about a missing delivery or cancellation?

Brello lists info@brellohealth.com and 1-888-BRELLO-1 for cancellation and refund inquiries. Its detailed missing-delivery procedure requires email within 48 hours and supporting documentation. Medication problems should be reported immediately to the dispensing pharmacy. Because the FAQ and detailed policy differ on delivered-but-missing packages, ask which procedure governs; do not assume replacement is automatic.

Sources: [3] [6]

Our assessment

Brello documents recognizable prepaid GLP-1 offers, specific renewal amounts, named pharmacy fulfillment and useful package inclusions. Its strongest cost information is the actual checkout charge—not the monthly average. The principal weaknesses are unresolved boundaries: week-based renewals beside month-based labels, price-lock language beside variable-pricing language, and conflicting refund and delivery provisions. Before paying, obtain a written quote identifying the medication and formulation, upfront charge, next renewal date, cancellation procedure, applicable refund policy and any outside-care costs. Also confirm state availability and the treating clinician’s identity. Brello may be straightforward to budget once those points are settled, but the supplied documents alone do not justify treating the advertised average as a complete or universally refundable cost of care.

Visit Brello Health’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Brello Health Review: The Upfront Price Behind Its Monthly GLP-1 Offers

At a glance

01Read the checkout charge before the monthly average

02Renewal promises need a plan-specific explanation

03What the advertised bundle includes—and what remains outside it

04Paying starts the process, not a guaranteed prescription

05Refund eligibility narrows as an order progresses

06Pharmacy choice can change the payment arrangement

07Delivery disputes can create another upfront expense

08Larger bundles and transfer protection need separate scrutiny